These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 33391463

  • 1. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z, Du J, Hui H, Kan S, Huo T, Zhao K, Wu T, Guo Q, Lu N.
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [Abstract] [Full Text] [Related]

  • 2. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
    Hu C, Zhang Y, Yang J, Xu Y, Deng T, Li Y, Xu S, Wang S, Wang P.
    Cell Commun Signal; 2024 Jul 08; 22(1):355. PubMed ID: 38978049
    [Abstract] [Full Text] [Related]

  • 3. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 4. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S.
    Leukemia; 2012 Jul 06; 26(7):1462-70. PubMed ID: 22354205
    [Abstract] [Full Text] [Related]

  • 5. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P, Xiao X, Zhang Y, Zhang B, Li D, Liu M, Xie X, Liu C, Liu P, Ren R.
    J Hematol Oncol; 2021 Jul 03; 14(1):105. PubMed ID: 34217323
    [Abstract] [Full Text] [Related]

  • 6. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC, Hellwig S, Tan L, Liu Y, Gray NS, Smithgall TE.
    PLoS One; 2017 Jul 03; 12(7):e0181178. PubMed ID: 28727840
    [Abstract] [Full Text] [Related]

  • 7. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B, Zhao Y, Wang X, Gong P, Ge W.
    Leukemia; 2017 Apr 03; 31(4):913-921. PubMed ID: 27773927
    [Abstract] [Full Text] [Related]

  • 8. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug 03; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 9. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.
    Yamaura T, Nakatani T, Uda K, Ogura H, Shin W, Kurokawa N, Saito K, Fujikawa N, Date T, Takasaki M, Terada D, Hirai A, Akashi A, Chen F, Adachi Y, Ishikawa Y, Hayakawa F, Hagiwara S, Naoe T, Kiyoi H.
    Blood; 2018 Jan 25; 131(4):426-438. PubMed ID: 29187377
    [Abstract] [Full Text] [Related]

  • 10. TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.
    Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, Levis M, Rudek M, Duffield A, Small D.
    Blood; 2014 Mar 06; 123(10):1525-34. PubMed ID: 24408321
    [Abstract] [Full Text] [Related]

  • 11. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR.
    Clin Cancer Res; 2018 Jan 01; 24(1):234-247. PubMed ID: 29074603
    [Abstract] [Full Text] [Related]

  • 12. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.
    Blood; 2013 Nov 21; 122(22):3607-15. PubMed ID: 24046014
    [Abstract] [Full Text] [Related]

  • 13. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H, Berrou J, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H, Braun T.
    Leuk Res; 2021 Jan 21; 100():106490. PubMed ID: 33373830
    [Abstract] [Full Text] [Related]

  • 14. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
    Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.
    J Hematol Oncol; 2013 Mar 16; 6():21. PubMed ID: 23497456
    [Abstract] [Full Text] [Related]

  • 15. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.
    Mol Cancer Ther; 2015 Oct 16; 14(10):2364-73. PubMed ID: 26206337
    [Abstract] [Full Text] [Related]

  • 16. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, Shimada I, Mori K, Kuromitsu S.
    Invest New Drugs; 2017 Oct 16; 35(5):556-565. PubMed ID: 28516360
    [Abstract] [Full Text] [Related]

  • 17. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
    Lee HK, Kim HW, Lee IY, Lee J, Lee J, Jung DS, Lee SY, Park SH, Hwang H, Choi JS, Kim JH, Kim SW, Kim JK, Cools J, Koh JS, Song HJ.
    Blood; 2014 Apr 03; 123(14):2209-19. PubMed ID: 24532805
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib.
    Uras IZ, Maurer B, Nebenfuehr S, Zojer M, Valent P, Sexl V.
    Int J Mol Sci; 2018 Dec 11; 19(12):. PubMed ID: 30544932
    [Abstract] [Full Text] [Related]

  • 19. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
    Yang X, Sexauer A, Levis M.
    Br J Haematol; 2014 Jan 11; 164(1):61-72. PubMed ID: 24116827
    [Abstract] [Full Text] [Related]

  • 20. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, Shen Y, Xiang RF, Wang LN, Wang L, Jiang CH, Jiang JL, Zhang WJ, Sun YD, Chang L, Gao WH, Wang Y, Li JM, Hong DL, Liang AB, Hu J.
    Blood; 2020 Apr 23; 135(17):1472-1483. PubMed ID: 32315388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.